A Post Approval Surveillance of Scemblix® (Asciminib) in Patients With Chronic Myeloid Leukemia (CML) in Korea
Status: Recruiting
Location: See all (14) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:
• Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label
• Patients who are willing to provide written informed consent prior to study enrollment
Locations
Other Locations
Republic of Korea
Novartis Investigative Site
RECRUITING
Gyeonggi-do
Novartis Investigative Site
RECRUITING
Incheon
Novartis Investigative Site
RECRUITING
Jeollanam
Novartis Investigative Site
RECRUITING
Pusan
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Taegu
Novartis Investigative Site
RECRUITING
Uijeongbu-si
Novartis Investigative Site
RECRUITING
Wŏnju
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: 2023-07-19
Estimated Completion Date: 2025-07-31
Participants
Target number of participants: 100
Treatments
Asciminib
Patients prescribed with Asciminib at physicians' discretion as per locally approved label under usual clinical practice
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals